scholarly journals IgA Nephropathy in a Patient Treated with Adalimumab

2021 ◽  
pp. 233-240
Author(s):  
Tonja Mertelj ◽  
Nataša Smrekar ◽  
Nika Kojc ◽  
Jelka Lindič ◽  
Damjan Kovač
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Iga Nephropathy ◽  
Immunoglobulin A ◽  
Necrosis Factor Alpha ◽  
Inflammatory Conditions ◽  
Remarkable Recovery ◽  
History Of ◽  
Factor Alpha ◽  
End Stage

Immunoglobulin A (IgA) nephropathy (IgAN) is the most common glomerulonephritis worldwide, characterized by IgA deposits in the glomerular mesangium. It has a progressive nature and can eventually lead to end-stage kidney failure. It can occur as a potential side effect of treatment with tumor necrosis factor alpha antagonist that has been used for numerous chronic inflammatory conditions, such as Crohn’s disease. In this study, the case of a 33-year-old man with renal dysfunction, nephrotic proteinuria, and erythrocyturia is described. He had had a history of Crohn’s disease for 8 years and had been treated with adalimumab for the past 7 years. The diagnosis of IgAN was confirmed by kidney biopsy. After discontinuance of adalimumab and the induction of corticosteroid therapy, he made a remarkable recovery. Four years after the first presentation of IgAN and discontinuation of adalimumab, his renal function was normal with no proteinuria and only mild erythrocyturia.

scholarly journals Infliximab: A Review of its use in the Treatment of Pediatric Crohn's Disease

2010 ◽  
Vol 2 ◽  
pp. CMT.S2840
Author(s):  
Arkady Broder ◽  
Joel R. Rosh
Keyword(s):  
Monoclonal Antibodies ◽  
Crohn’S Disease ◽  
Chronic Disease ◽  
Crohn's Disease ◽  
Tumor Necrosis ◽  
Immune Dysregulation ◽  
Necrosis Factor Alpha ◽  
The Past ◽  
Factor Alpha ◽  
Necrosis Factor

The past decade has brought great change to the treatment of pediatric Crohn's disease. The majority of affected patients now receive therapy directed at the underlying immune dysregulation that is associated with this chronic disease. The monoclonal antibodies directed against tumor necrosis factor alpha play an increasing role in such therapy. Infliximab is the prototype of this class of biologic based therapy. This review covers the basic pharmacokinetics of infliximab while reviewing the data on its efficacy in pediatric Crohn's disease patients. Current issues related to infliximab dosing and safety are also reviewed.

scholarly journals Esophageal post-inflammatory polyposis in extensive and severe Crohn’s disease treated with anti-tumor necrosis factor alpha

Endoscopy ◽  
2016 ◽  
Vol 48 (S 01) ◽  
pp. E261-E262 ◽  
Author(s):  
Paola Soriani ◽  
Gian Tontini ◽  
Helmut Neumann ◽  
Sauid Ishaq ◽  
Maria Annunziata ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Tumor Necrosis Factor ◽  
Crohn's Disease ◽  
Tumor Necrosis Factor Alpha ◽  
Tumor Necrosis ◽  
Necrosis Factor Alpha ◽  
Factor Alpha ◽  
Inflammatory Polyposis ◽  
Necrosis Factor

Short-term outcomes of laparoscopic surgery for Crohn’s disease patients treated with anti-tumor necrosis factor alpha agents

Surgery Today ◽  
2016 ◽  
Vol 47 (3) ◽  
pp. 320-327 ◽  
Author(s):  
Tsuyoshi Hata ◽  
Tsunekazu Mizushima ◽  
Hideki Osawa ◽  
Hidekazu Takahashi ◽  
Naotsugu Haraguchi ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Laparoscopic Surgery ◽  
Tumor Necrosis Factor ◽  
Crohn's Disease ◽  
Tumor Necrosis Factor Alpha ◽  
Tumor Necrosis ◽  
Short Term ◽  
Necrosis Factor Alpha ◽  
Factor Alpha ◽  
Necrosis Factor
Sign in / Sign up

Export Citation Format

Share Document